MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: Strategic Corporate Investment & Corporate Venture Capital (CVC)
Portfolio Companies: Biogen IDEC:
Macrogenics, Inc. (NASDAQ: MGNX)*
Organization & Developments: Macrogenics
Parents
Macrogenics, Inc. (NASDAQ: MGNX)*
Children
*A Mab directed to CD32B is expected to enter into early stage clinical trials in B-cell malignancies
*Also plan to advance treatments for other autoimmune diseases such as arthritis and multiple sclerosis
*Biotech spinoff of the Seattle-based Institute for Systems Biology
*CD16-blocking Mab, which is being co-developed with Genzyme Corporation, is in a Phase 1 clinical trial for idiopathic thrombocy
*Developing immunotherapeutics
*MacroGenics is developing a monoclonal antibody to treat West Nile virus neurological disease and a vaccine to prevent West Nile
*MacroGenics is focused on the develompent and commercialization of biologics for the treatment of autoimmune disorders, cancer and infectious diseases.
*Other molecules emerging from MacroGenics’ proteomics and Fc receptor programs will be advanced through preclinical development
*Plan to use money to support international Phase 2/3 trial of a CD3 monoclonal antibody (Mab) for Type 1 diabetes mellitus
*The company’s proprietary Fc engineering technology offers ways of improving antibody function
2011: MacroGenics signs big pharma deal with Servier (2011)
2014: Maryland Biotech _ MedImmune, GlycoMimetics and MacroGenics announce cancer drug trials
2017: MacroGenics' Deal With Incyte Just The Beginning - MacroGenics, Inc. (NASDAQ:MGNX)
2017: My Take On MacroGenics_seekingalpha
2018: MacroGenics: Low Hanging Fruit_seekingalpha.com
2019: MacroGenics: Updating The Investment Thesis_seekingalpha.com
2019: UPDATED: MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin
2020: MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte Nasdaq:MGNX
2020: The Play On MacroGenics
2021: MacroGenics: A Look At The DART Platform
2021: MacroGenics: Pipeline Looks Very Attractive And Somewhat Overlooked
2022: Gilead grabs MacroGenics’ blood-cancer focused bispecific in $1.76B license-option deal
2022: In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial
2022: MacroGenics joins biotech layoff wave, slashing 15% of workforce after deaths reported in phase 2 trial
2022: MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials_seekingalpha.com
2022: MacroGenics: No Near-Term Catalysts_seekingalpha.com
2024: MacroGenics Faces Uncertainty After Vobra Duo Setback
2024: MacroGenics passes off struggling breast cancer med Margenza to TerSera for $40M plus milestones
2024: MacroGenics pauses work on ADC pending mature survival data
2024: MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
2024: MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects
2024: MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
2024: MacroGenics: Trying To Build A Better Everything
2024: MacroGenics' stock crashes after 5 deaths in ADC trial
2025: MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
2025: MacroGenics' new CEO Risser aims to cut costs, boost revenue
2026: MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Developing immune-based products including monoclonal antibodies to treat patients with
Jumps
*Key People: Macrogenics
Finance & Acquisition: Macrogenics